Effectiveness and tolerability of the new antiepileptic drugs: The position of levetiracetam;Eficacia y tolerabilidad de los nuevos antiepilépticos: Posición del levetiracetam

Revista de Neurologia

Volumn 35, Issue 3, 2002, Pages 227-230

  Arroyo, Santiago ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Antiepileptics; Clinical trials; Epilepsy; Levetiracetam; Partial seizures

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HUMAN; MONOTHERAPY; REVIEW; SIDE EFFECT;

EID: 0036705108     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3503.2002136     Document Type: Review

References (14)

1. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: A systematic review of their efficacy and tolerability. Br Med J 1996; 313: 1169-74.
2. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia 1997; 38: 859-80.
3. Marson AG, Hutton JL, Leach JP, Castillo S, Schmidt D, White S, et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: A systematic review. Epilepsy Res 2001; 46: 259-70.
4. Cramer JA, Fisher R, Ben Menachem E, French J, Mattson RH. New antiepileptic drugs: Comparison of key clinical trials. Epilepsia 1999; 40: 590-600.
5. Cramer JA, Ben Menachem E, French J. Review of treatment options for refractory epilepsy: New medications and vagal nerve stimulation. Epilepsy Res 2001; 47: 17-25.
6. Elferink JA, van Zwieten-Boot BJ. New antiepileptic drugs. Analysis based on number needed to treat shows differences between drugs studied. Br Med J 1997; 314: 603.
7. Van Rijckevorsel K, Boon PA. The 'number needed to treat' with Levetiracetam (LEV): Comparison with the other new antiepileptic drugs (AEDs). Seizure 2001; 10: 235-6.
8. Lesaffre E, Boon P, Pledger GW. The value of the numberneeded-to-treat method in antiepileptic drug trials. Epilepsia 2000; 41: 440-6.
9. Wong IC, Chadwick DW, Fenwick PB, Mawer GE, Sander JW. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 1999; 40: 1439-45.
10. Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000; 41: 338-41.
11. Krakow K, Walker M, Otoul C, Sander JWAS. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772-4.
12. Abou-Khalil B. Long-term seizure freedom with levetiracetam, Epilepsia 2000; 41 (Suppl): S38.
13. Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56: 411-2.
14. Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001; 57: 1112-4.